Abstract Airway smooth muscle (ASM) is a key target cell in allergen-induced asthma known to contribute to airway hyperresponsiveness (AHR) and chronic airway remodeling. Changes in ASM calcium homeostasis have been shown to contribute to AHR although the mechanisms and Ca 2+ signal effectors are incompletely understood. In the present study, we tested the function of ASM multifunctional protein kinase Ca 2+ /calmodulin-dependent kinase II (CaMKII) isoforms CaMKIIδ and CaMKIIγ in allergen-induced AHR and airway remodeling in vivo. Using a murine model of atopic asthma, we demonstrate that CaMKIIδ protein is upregulated in ASM derived from ovalbumin (OVA)-treated animals compared to controls. A genetic approach to conditionally knock out smooth muscle CaMKIIδ and CaMKIIγ in separate Creloxp systems was validated, and using this loss-of-function approach, the function of these CaMKII isoforms was tested in ovalbumin (OVA)-induced airway remodeling and AHR.
Introduction
Airway smooth muscle (ASM), a major structural component of the airway, is strongly implicated in the pathophysiology of atopic asthma. Drug therapies targeting ASM contractile activity, or bronchial thermoplasty targeting ASM viability, decrease airway hyperresponsiveness (AHR) and improve symptoms in asthmatics [10, 11] . Still, there is considerable debate over the exact role(s) ASM plays in the pathophysiology of asthma [17, 39] .
Smooth muscle cells, including ASM, exhibit phenotypic modulation in response to environmental cues, switching between a differentiated, quiescent contractile phenotype and a Bsynthetic^phenotype which is motile and proliferative [19, 37] . Although important during development and physiological adaptations to stress and injury, unregulated smooth muscle phenotypic changes may also promote disease pathologies including airway remodeling associated with chronic asthma [38, 58] . Recently, in vitro studies in ASM cells have shown that these cells respond to stimulation with cytokines, such as IL-1β and TNF-α, by expressing inflammatory marker proteins including intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) [2, 30] . Furthermore, ASM has been shown to secrete various proinflammatory cytokines including granulocyte-macrophage colony-stimulating factor (GM-CSF) [45] , IL-6, IL-11 [14] , IL-5, interferon gamma (IFN-γ) [18] , and chemokines, including RANTES (regulated on activation, normal T cell expressed) and eotaxin [7, 25] . These studies provide evidence that ASM may acquire a pro-inflammatory phenotype leading to both recruitment and adhesion of inflammatory cells to sites of allergen-induced mucosal injury [42, 53] . However, there is little direct in vivo evidence for this important concept, as in vivo model systems to detect and manipulate the interplay between activated inflammatory cells and asthmatic ASM are lacking.
Changes in calcium homeostasis in ASM cells exposed to inflammatory factors promote allergen-induced airway responses [55] . For example, we recently demonstrated that stromal interaction molecule 1 (STIM1) and Ca 2+ -release-activated Ca 2+ channel protein 1 (Orai1), two proteins involved in store-operated Ca 2+ entry (SOCE) [16] , are upregulated in a murine model of allergen-induced asthma. Silencing expression of these proteins inhibited PDGF-induced Ca 2+ entry into ASM cells and Ca 2+ -release-activated Ca 2+ (CRAC) current [51] . One ubiquitously expressed family of effector proteins regulated by intracellular Ca 2+ signals is multifunctional Ca 2+ /calmodulin-dependent protein kinase II (CaMKII). CaMKII is a multigene family with CaMKIIδ and CaMKIIγ (Camk2d and Camk2g genes, respectively) being the predominant isoforms expressed in vascular smooth muscle [20] . Recent studies in human asthmatics and a murine model of asthma linked increases in oxidation and activation of CaMKII to NF-κB-mediated transcription of inflammatory factors in airway epithelial cells. Using general pharmacological inhibitors of CaMKII administered intranasally, allergeninduced AHR and airway remodeling were prevented confirming the role of this kinase in atopic asthma [44] . However, the expression and function of specific CaMKII isozymes in ASM physiology and pathophysiology are poorly characterized.
In this study, we test the hypothesis that CaMKIIδ regulates ASM function in allergen-induced AHR. A murine model of ovalbumin (OVA)-induced AHR was used which recapitulates aspects of the human inflammatory response in asthmatics, including goblet cell hyperplasia, epithelial cell hypertrophy, elevated IgE, AHR, and overall airway inflammation [35] . We show for the first time upregulation of CaMKIIδ protein expression in ASM in response to OVA sensitization and challenge in allergen-induced AHR in vivo. Mice with smooth muscle deletion of CaMKIIδ were produced by breeding animals with floxed Camk2d alleles [5] with those harboring a Transgelin (SM22α) promoter driving a Cre recombinase transgene [26] . In conditional CaMKIIδ knockout animals, allergen-induced AHR was delayed. This was a CaMKII isoform specific phenomenon as OVA-induced AHR in conditional knockout mice of CaMKIIγ was similar to controls. OVA-induced inflammatory responses were attenuated in CaMKIIδ knockouts as assessed by extent of peribronchial infiltrate and BALF concentration of the inflammatory cytokine IL-13. These studies for the first time implicate a function for ASM CaMKIIδ in promoting allergen-induced AHR in vivo and suggest a role for this kinase in promoting a proinflammatory ASM phenotype.
Materials and methods
Mouse models Tagln;Cre reporter animals were created by crossing transgenics expressing Cre recombinase under control of a Transgelin (SM22α) promoter [26] (B6.CgTg(Tagln-cre)1Her/J; Jackson labs) with a reporter line (mTmG) expressing either membrane-localized tdTomato or GFP (B6.129(Cg)-Gt(ROSA) 26Sor tm4(ACTB-tdTomato-EGFP)luo / J; Jackson Labs). CaMKIIδ and CaMKIIγ smooth muscle knockout mice were produced by breeding mixed background B6;129; FVB mice harboring floxed Camk2 alleles with the Tagln;Cre transgenics. Camk2γ f/f [6] and Camk2δ f/f founders [5] were provided by Drs. Johannes Backs (Univ. of Heidelberg) and Eric Olsen (UT Southwestern). All animal procedures were carried out with protocols approved by the Albany Medical Center Institutional Animal Care and Use Committee.
Sensitization/challenge protocol Three-to 4-week-old males were sensitized by intraperitoneal injection of ovalbumin (OVA; 25 μg) plus aluminum hydroxide adjuvant (2 mg) in 0.5 ml sterile physiological salt solution (PSS) weekly for 3 weeks. The intraperitoneal (IP) injections were followed by challenge with OVA (100 μg in 25 μl PSS intranasal) daily for 10 days [51] . Controls received PSS. Mice were studied using the forced oscillation techniques and/or euthanized by overdose of sodium pentobarbital (100 μg/g IP) for tissue harvesting 24 h post-final challenge.
Airway mechanics Mice were analyzed 1 or 7 days postfinal challenge. Animals were anesthetized by IP injection with xylaxine (0.01 mg/g) and ketamine (0.1 mg/g). Animals were tracheotomized and connected to a computer-controlled small animal mechanical ventilator, part of the FlexiVent operating system (SCIREQ, Montreal, PQ, Canada). The animals were then paralyzed with an IP injection of pancuronium bromide (0.8 mg/kg). Measurements were taken after administration of increasing aerosolized doses of methacholine (Mch; 0, 3.8, 7.5, 15, 30, 60, and 100 mg/ml). Preprogrammed single frequency snapshot perturbation was executed by the FlexiWare7 software (SCIREQ). The software inputs resulting data into a mathematical single compartment model and outputs systemic airway resistance (Rrs) values at each concentration of Mch. For all perturbations, a coefficient of determination (COD) of 0.90 was determined to be the limit of the lower range for measurement acceptance.
BALF IL-13 analysis Bronchoalveolar lavage fluid (0.75 ml PSS) was collected from euthanized mice and centrifuged (5000 rpm, 1 min). Interleukin-13 (IL-13) was quantified by enzyme-linked immunoassay (ELISA; R&D Systems, Minneapolis, MN).
Immunoblotting Tracheobronchial tissue was harvested, epithelium mechanically removed, and lysates prepared as described previously [20] . Western blotting was by standard methods. Antibodies used for the study included rabbit antipeptide antibodies specific for the C-terminus in CaMKIIδ2 P S C I P N G K E N F S G S T S LW Q N I a n d C a M K I I γ (aa 567 LNVHYHCSGAPAAPL 581 ), as previously described [20, 48] . GAPDH (Sigma) was used as a loading control. Secondary HRP-conjugated anti-rabbit IgG (GE Healthcare) chemiluminescent signals (SuperSignal, West Pico) were imaged and quantified with a Fuji LAS4000 Imaging Station.
Immunohistochemistry
Tissue analysis of Tagln-Cre reporter mice Lungs were harvested, embedded in OCT, and sectioned for imaging of lower airway fluorescence. Imaging of trachealis (cleaned of epithelium) was on a glass bottom culture dish (MatTek) in HBSS (Cellgro). Confocal fluorescence microscopy was carried out on a Zeiss LSM 510META.
Smooth muscle area analysis Smooth muscle area was quantified by IHC staining using a primary antibody specific for smooth muscle alpha actin (α-SMA; Abcam) using Vectastain Elite ABC Kit (Vector Laboratories) for detection.
Smooth muscle area was quantified from ×40 images using the ImageJ Color Deconvolution plugin to separate out Nova Red initiated stain. Images were thresholded to remove background and the area of signal was determined. Length of basement membrane was determined using ImageJ freehand line tool to normalize smooth muscle area measurement to airway size.
Airway inflammation analysis Lungs were harvested from euthanized animals and fixed overnight in 10 % buffered formalin (Fisher Scientific, Fair Lawn, NJ), dehydrated, and embedded in paraffin blocks. Five-micrometer sections were cut and recovered on Superfrost Plus slides (Fisher Scientific, Fair Lawn, NJ). Sections were stained with hematoxylin and eosin (H&E; Thermo Scientific). Lower airways (~100-200 μm in diameter) were examined at ×20 magnification (×100 magnification for infiltrate assessment) on an Olympus BX51 microscope. Quantification of the extent of peribronchial infiltrate was determined by a measurement adapted from a previous publication [13] . ImageJ freehand line tool was used to trace the total length of the airway lumen. The length of the lumen covered by infiltrate was then assessed and a percentage of airway covered by infiltrate was determined. Peribronchial infiltrate depth was quantified using the ImageJ straight line tool. Each airway was analyzed to locate the area where the infiltrate was the deepest, and the length of this infiltrate was then quantified.
Infiltrate characterization Paraffin lung sections obtained from processed lungs as described above were used to determine the number of peribronchial eosinophils using rat antimouse eosinophil antibody (anti-MPB-a generous gift from Dr. Jamie Lee, Mayo Clinic), peribronchial neutrophils, and peribronchial macrophages using mouse anti-Ly-6C Ly-6G antibody (BD Pharmingen) that recognizes both leukocytes. Distinction between the two leukocytes was determined by assessing nuclear morphology; Ly6C+/6G+ cells with a polymorphonucleaus were counted as neutrophils while Ly6C+/6G+ cells with a uniform nuclear morphology were counted as a macrophage. Lymphocytes were detected using the T lymphocyte antibody (anti-CD3, Abcam). Data represents leukocyte per unit area. Sections were cleared and rehydrated as described above. Heat-mediated antigen retrieval was carried out when staining for lymphocytes, macrophages, and neutrophils using the Citric Acid-EDTA Buffer. When staining for eosinophils, antigen retrieval was carried out using pepsin (0.5 % in 5 mM HCl) at room temperature. Slides were washed in 1× phosphate-buffered saline (PBS) and then endogenous peroxidase activity was quenched by incubating samples in 3 % H 2 O 2 for 20 min at room temperature. Lungs were then stained with Vectastain ABC Kit (vector Laboratories) with Nova Red chromagen. Sections were further counterstained with hematoxylin (Thermo Scientific).
Immunofluorescence staining Ten percent buffered formalin fixed lungs were cyroprotected by incubation with serial 0.1 M glycine washes at (4°C) for 1 h and stored in 0.6 M sucrose (4°C) overnight, embedded in optimal cutting temperature (OCT) embedding compound (Tissue-Tek), and snap frozen in liquid nitrogen. Ten-micrometer frozen sections were rinsed in 1× PBS and permeabilized with pre-cooled acetone at 4°C. Tissue was blocked with buffer containing 1× PBS, 5 % goat serum (MP Biomedicals), 0.5 % fish gelatin, and 0.1 % TritonX-100 (Sigma). Staining of lung sections was performed by direct fluorescence using the following antibodies: α-smooth muscle actin (α-SMA) antibody conjugated to Cy3 (Sigma), and indirect fluorescence using an antibody specific for the C-terminus of CaMKIIδ [48] , SM-MHC (Biomedical Technologies), and α-SMA antibody (Abcam). Appropriate secondary antibodies were used including antirabbit secondary antibodies (488, 647 nm; Molecular Probes) in order to detect signal. Sections were mounted with aqueous mounting medium Fluoromount-G (SouthernBiotech) or Vectshield with dapi (Vector). Confocal microscopy was carried out on processed sections with a Zeiss laser scanning microscope (LSM) 510META at ×63 magnification.
ASMC dispersion and culture Mouse airway smooth muscle cells (ASMCs) were obtained from the tracheobronchial tissue of airways derived from 9-week-old male δf/f; smCreor δf/f; smCre+ animals. Following the removal of epithelial cells ASM cells were enzymatically dispersed and cultured in DMEM-Ham's F-12 with 10 % fetal bovine serum. The mouse ASMCs were maintained at 37°C in a 5 % CO 2 -95 % humidity atmospheric environment. Cells were split two times weekly and media was changed every 3 days. Experiments were carried out on passages 3-7.
Inflammatory cocktail treatment
δf/f; smCre-and δf/f; smCre+ ASMCs were treated with either 0.4 % fetal bovine serum (FBS) or with an inflammatory cocktail consisting of IL-1β (20 ng/ml), TNF-α (20 ng/ml), and IFNγ (200 u/ml) in 0.4 % FBS for 6 h. After 6 h, total RNA was extracted as described below.
Quantitative PCR Total RNA was extracted from mouse airway smooth muscle by homogenization in Trizol (Invitrogen, Carlsbad, CA) and first-strand cDNA synthesized using QuantiTect Reverse Transcription (Qiagen, Valencia, CA). Quantitative RT-PCR was performed on Mx3000P QPCR System (Agilient, Santa Clara, CA) using iQ SYBR Green supermix (Bio-Rad, Hercules, CA). The primers for mouse target genes and internal controls were as follows: camk2d forward 5′-GAC GAG TAT CAG CTC TTT GAG G-3′, and reverse 5′-GTT TCT GAT GGT CCC TAG CAG-3′; camk2g forward 5′-CGA CTA CCA GCT TTT CGA GG-3′, and reverse 5′-GCC TCT CGT TCT AGT TTC TGA TG-3′; GAPD H forward 5′-TCC ATG ACA ACT TTG GCA TTG-3′, and reverse 5′-TCA CGC CAC AGC TTT CCA-3′; eotaxin forward 5′-GCTCCATCCCAACTTCCTG-3′, and reverse 5′-AGATCTCTTTGCCCAACCTG 3′; MMP9 forward 5′-GATCCCCAGAGCGTCATTC-3′, and reverse 5′-CCACCT TGTTCACCTCATTTTG-3′; and IL-33 forward 5′-TTCCAA CTCCAAGATTTCCCC-3′, and reverse 5′-CAGAACGGAG TCTCATGCAG-3′.
Statistical analysis All data are expressed as means±SEM. Statistical tests were performed using GraphPad Prism 4 software and are reported in the figures.
Results

CaMKIIδ is upregulated in allergen-induced asthma
Mice were sensitized by intraperitoneal (IP) injection of ovalbumin (OVA) and adjuvant aluminum hydroxide, once a week for 3 consecutive weeks followed by daily challenge with intranasal OVA for 10 days ( Fig. 1a ; adapted from Schramm et al. 2004 [47] ). One day post-final challenge, hematoxylin and eosin (H&E) staining confirmed intense peribronchial cellular infiltrate and mucosal hypertrophy indicative of a strong inflammatory response in OVA-treated animals compared to PSS treated controls (Fig. 1b) . Airway dynamics were assessed using the forced oscillation technique (FlexiVent, SCIREQ). Using systemic airway resistance (Rrs) as the endpoint, OVA-treated animals were found hyperresponsive to increased concentrations of the contractile agonist methacholine compared to control animals (Fig. 1c) , a characteristic response of allergic airways to contractile agonists. T helper 2 cells (Th2) are known to drive the inflammatory response in asthmatic airways, and one major proinflammatory cytokine secreted by these cells is interleukin 13 (IL-13) [12, 57] . IL-13 levels in bronchoalveolar lavage fluid (BALF) measured by ELISA were found to be markedly increased in OVA-challenged animals compared to controls (Fig. 1d) .
Expression of Ca
2+
-signaling-related proteins including SOCE channel proteins STIM1 and Orai1 [51] and sarcoendoplasmic reticulum Ca 2+ -ATPase (SERCA) [31] is known to be modulated in asthmatic ASM. As an intracellular mediator of Ca 2+ signaling, CaMKII expression in ASM was determined by Western blotting tracheobronchial smooth muscle extracts with antibodies that specifically distinguish the Cterminus of CaMKIIδ and γ isoforms [20, 48] . CaMKIIδ protein was upregulated 1.5-fold in OVA-treated animals as compared to controls (Fig. 2a, b) with a corresponding small but significant decrease in the expression of CaMKIIγ in asthmatic airways (Fig. 2c, d ). Indirect immunofluorescence confirmed CaMKIIδ expression in lower airways from both control and asthmatic animals and co-localization with ASM as detected by staining with α-smooth muscle actin (Fig. 2e) .
Genetic deletion of CaMKIIδ expression in ASM
To determine the function of ASM CaMKIIδ in atopic asthma, conditional knockout mice were developed by breeding mixed background mice harboring Camk2d floxed alleles [5] with transgenics containing Cre recombinase under control of a 2.8-kb Transgelin (SM22α) promoter (B6.Cg-Tg(Tagln-cre)1Her/J) [26] . Previous work using alternative versions of the SM22α promoter were inconclusive regarding its activity in bronchial and tracheal smooth muscle [28, 34] . In order to localize expression of Tagln-Cre in this system, the transgenics were crossed to a double fluorescent reporter line expressing membrane-targeted tdTomato (an RFP mutant) or membrane-targeted EGFP (BmTmG^mice), depending on Cre recombinase activity. In this system, mT is constitutively expressed while Cre activity deletes the floxed mT allele and puts in frame the EGFP allele. In the airways of Tagln-Cre(−);mTmG animals, EGFP was not detected in the lower airway smooth muscle (Fig. 3a) . In the double Tagln-Cre(+);mTmG transgenic, EGFP fluorescence was detected submucosally in the walls of lower airways and pulmonary blood vessels (Fig. 3b) , consistent with localization in lower ASM and vascular smooth muscle. Compared to expression levels of mG in Cre(−) animals (Fig. 3c) , mG expression was found to be stronger in tracheobronchial tissue (Fig. 3d) . These results confirm activity of Tagln-Cre throughout the airway tree of the transgenics.
Given evidence of Tagln-Cre activity in ASM, Camk2d (f/f) mice were bred with Tagln-Cre (+/−) to produce conditional smooth muscle CaMKIIδ knockouts and littermate controls. The extent of CaMKIIδ knockout was evaluated by qPCR of CaMKIIδ messenger RNA (mRNA) in tracheobronchial layer extracts containing predominantly ASM. CaMKIIδ expression decreased by 68 % in the Cre + animals (Fig. 3e) , with no compensatory increases in CaMKIIγ expression (Fig. 3f) . In lysates from enzyme-dispersed cells from tracheobronchial tissue, CaMKIIδ knockout was nearly complete at the protein level (Fig. 3g, h ). Based on these results, we concluded that Tagln-Cre activity efficiently deleted CaMKIIδ in ASM cells with a residual low expression most likely originating from contaminating cell types in the complex tracheobronchial tissue.
Allergen-induced AHR is ameliorated in smooth muscle conditional CaMKIIδ KO mice but not CaMKIIγ KO mice
In order to evaluate function of smooth muscle CaMKIIδ in allergen-induced AHR, systemic airway resistance (Rrs) was assessed using the Flexivent system in OVA-challenged 
CaMKIIδ knockout mice (δf/f; smCre+) and littermate controls (δf/f; smCre-). Conditional deletion of smooth muscle CaMKIIδ had no effect on baseline responsiveness to methacholine in saline-treated controls (Fig. 4a, solid lines) , suggesting no intrinsic changes in contractility in the conditional knockouts. Remarkably, the characteristic OVAinduced hyperresponsiveness to methacholine observed in control mice was completely absent in δf/f; smCre+ mice lacking smooth muscle CaMKIIδ (Fig. 4a) . Parallel studies were conducted in mice with smooth muscle conditional knockout of CaMKIIγ isoform expression. OVA-induced AHR (Rrs) were unaffected in the CaMKIIγ knockouts, indicating an isoform-specific function for smooth muscle CaMKIIδ in promoting OVA-induced AHR (Fig. 4b) .
Allergen-induced AHR is independent of ASM remodeling or alterations in contractile proteins
We showed previously that increased expression of CaMKIIδ promotes vascular smooth muscle proliferation and migration in vitro [20, 33] and vascular remodeling in response to balloon-angioplasty-induced injury in vivo [21] . In this model of OVA-induced AHR, no increases in ASM area were observed in control OVA-treated δf/f; smCre-mice compared to saline controls (Fig. 5a ) and smooth muscle deletion of CaMKIIδ had no effect on either baseline ASM content in saline treated animals, or on ASM content in OVA-treated animals (Fig. 5b) . Similarly, no OVA-induced changes in protein expression of the smooth muscle specific contractile marker, smooth muscle myosin heavy chain (SM-MHC), were observed (Fig. 5c) , suggesting a lack of effect of CaMKIIδ deletion on ASM contractile phenotype. From these results, we conclude that AHR in this specific OVA-challenge model is independent of ASM remodeling and that smooth muscle CaMKIIδ deletion has no effect on baseline ASM structure or contractile markers.
Allergen-induced inflammatory response is attenuated in smooth muscle CaMKIIδ knockout mice
To identify the effect of smooth muscle CaMKIIδ deletion on the process of acute inflammatory cell infiltration [24] , lung sections were examined by H&E staining (Fig. 6a) . Extent of peribronchial inflammation (circumference covered) in response to OVA challenge was significantly decreased by 49 % in smooth muscle CaMKIIδ knockouts (δf/f; smCre+) compared to littermate controls (δf/f; smCre-) (Fig. 6b) . As a separate index, the depth of peribronchial infiltrate was also reduced to a similar extent in CaMKIIδ knockout compared to control animals (Fig. 6c) . Consistent with decreased extent of inflammatory cell infiltrate, IL-13 concentrations in BALF was reduced by about 70 % in allergen-challenged CaMKIIδ knockouts compared to littermate controls (Fig. 6d) .
Leukocyte-specific antibodies were used to stain eosinophils, lymphocytes, neutrophils, and macrophages in serial lung sections derived from lungs harvested 1 day after final challenge ( Fig. 7a-d) . Areas of dense peribronchial infiltrate were examined using a high powered objective (×100), and the relative number of specific leukocytes per unit area was determined after examining the entire image (Fig. 7e) . We observed a decrease in the content of lymphocytes and macrophages in CaMKIIδ knockout animals as compared to OVA-challenged wild-type animals, while the occurrence of intact eosinophils was significantly higher in the peribronchial space of airways from OVA-challenged CaMKIIδ knockouts compared to OVA-challenged controls. Eosinophils have been strongly linked to initiating airway remodeling in allergic asthma [56] . The presence of this granulocyte is transient; however, upon secretion of their granular contents, these cells are cleared from the airway during the resolution phase of injury [15, 32] . Our results showing higher eosinophil count in OVAchallenged CaMKIIδ knockouts suggest that the inflammatory response in OVA-challenged δf/f; smCre+ animals is delayed rather than prevented. Indeed, at the later time point of 7 days after final OVA challenge (instead of 1 day post-final OVA challenge as depicted in Figs. 1 and 4) , allergen-induced AHR was resolved in OVA-treated control δf/f; smCre-animals, while OVA-treated δf/f; smCre+ knockouts were hyperrespponsive to methacholine treatment. (Fig. 7f) .
CaMKIIδ regulates cytokine-dependent upregulation of IL-33 in cultured ASM cells
ASM themselves have been shown to initiate a proinflammatory transcriptional profile when stimulated by various inflammatory factors, secreting growth factors and adhesion molecules, further propagating the inflammatory cascade. Recently, CaMKII has been linked to the activation of this profile in cultured human ASM cells [30] . To identify if ASM CaMKIIδ regulates the transcription of pro-inflammatory cytokines, we assessed the level of mRNA expression of the eosinophil chemokine eotaxin, the matrix metallopeptidase 9 (MMP9), and the recently identified IL-1 family member, interleukin-33 (IL-33). IL-33 has been shown to be upregulated in asthmatic airways [41] . This cytokine promotes the differentiation of T helper (Th) and innate lymphoid type 2 cells (ILC2) into a Th2 phenotype, inducing the secretion of pro-inflammatory cytokine IL-13 [46] . ASM cells from wild type and CaMKIIδ knockout were treated with an inflammatory cytokine cocktail consisting of IL-1β, TNF-α, and IFN-γ for 6 h, and the extent of eotaxin, MMP9, and IL-33 mRNA induction was quantified by qPCR (Fig. 8) . IL-33 mRNA levels were attenuated by 60 % in ASM cells derived from CaMKIIδ knockout animals as compared to ASM cells from control animals. There were no significant differences in induction of eotaxin or MMP9 expression between the two cell lines.
Discussion
Airway smooth muscle (ASM) cells are both a target and a source of inflammatory mediators that promote allergeninduced AHR and remodeling [3, 4] . Ca 2+ and oxidative signaling through the multifunctional serine/threonine protein kinase, CaMKII, has been shown to promote inflammatory responses in various cell types, including cardiomyocytes [29] . The present study for the first time implicates a specific function for the CaMKIIδ isoform in promoting ASM pro- Fig. 5 Smooth muscle CaMKIIδ deletion does not affect ASM remodeling or contractile phenotype. a Representative lung sections from Saline (A1) and OVA (A2) challenged control animals (δf/f; smCre-) were analyzed for α-SM actin staining using immunohistochemistry. Black arrows indicate ASM; arrowheads indicate VSM in blood vessels. Images are taken at ×40 magnification. b Smooth muscle area was quantified in controls (δf/f; smCre-) and smooth muscle CaMKIIδ knockouts (δf/f; smCre+) using ImageJ de-convolution plugin and normalized by airway circumference of basement membrane (BM). Values are means±SEM; n=number of animals; 18 airways from each animal were averaged. There were no statistical differences between groups using two-way ANOVA with a Bonferroni post-hoc test. c Lung sections were imaged by confocal microscopy with ×40 objective. Lung sections harvested 24 h after final challenge were stained with SM-MHC (green) using indirect immunofluorescence. Qualitative assessment of SM-MHC protein expression in the lower airway of representative lung sections shows minimal changes in the extent of expression in saline challenged δf/f; smCre-animals, saline challenged δf/f; smCre+, OVA challenged δf/ f; smCre-and OVA challenged δf/f; smCre+ animals inflammatory function in vivo in a murine model of allergeninduced AHR. Recently, CaMKII oxidation and activity were shown to be increased in airway epithelium in bronchial biopsy specimens from severe asthmatic patients as well as in a murine model of atopic asthma [44] . Inhibition of CaMK activity using molecular/genetic approaches or by inhaled KN-93, a CaMKII inhibitor [52] , strongly attenuated AHR and inflammation in the mouse model. While that study highlighted the role of CaMKII as a mediator and therapeutic target in atopic asthma, it did not examine CaMKII-isoform-specific functions and was focused on CaMKII activity and function in airway epithelium. Together, these in vivo studies emphasize the role of CaMKII in the pathophysiology of atopic asthma and highlight the complex interplay of Ca 2+ and ROS signaling pathways and airway/immune cell interactions in the promotion of the asthmatic phenotype.
Four differentially expressed genes (α, β, δ, γ) encode CaMKII [54] which is expressed in vivo as a large heteromultimeric holoenzyme composed of 12 protein kinase subunits [22] . We determined that CaMKIIδ and γ isoforms were primarily expressed in differentiated ASM, similar expression patterns in differentiated vascular smooth muscle (VSM) [20] . Significantly, ovalbumin sensitization and challenge resulted in induced CaMKIIδ upregulation relative to CaMKIIγ in tracheal smooth muscle, correlating with marked AHR and extensive airway inflammation. Smooth-muscle- specific CaMKII knockout mouse models were employed in this study. The lineage tracing approach was first used to verify expression of Tagln;Cre in ASM surrounding both large conducting airways and lower airways. After verification of Cre expression in peripheral ASM, we were able to use these animals to test the function of specific CaMKII isoforms in the induction of allergen-induced AHR. Although application of conditional smooth muscle knockout mouse models has been widely applied in studies of vascular smooth muscle (VSM) biology and pathophysiology, only one other set of studies has been reported using a similar approach with a smooth muscle myosin heavy chain (Myh11);Cre line to study ASM biology and function in vivo. Employing this novel transgenic system, we determined that OVA-induced AHR and airway inflammation were absent in mice with smooth muscle conditional CaMKIIδ knockout. This effect was specific for the CaMKIIδ isoform as conditional deletion of CaMKIIγ had no significant effects on OVA-induced AHR, indicating non-equivalent functions of closely related CaMKIIδ and γ isoforms in this system.
Smooth muscle CaMKIIδ knockout had no effect on baseline methacholine reactivity in saline-treated animals, arguing for a lack of CaMKIIδ effect on intrinsic ASM contractility. However, OVA-induced AHR, as defined by increased systemic airway resistance (Rrs), failed to develop in CaMKIIδ knockout animals. The absence of OVA-induced alterations in ASM remodeling or changes in contractile protein expression in this model led us to focus our attention on the OVA-induced inflammatory response as a potential target for the Bprotective^effect on AHR observed in CaMKIIδ knockout mice. Total OVA-induced inflammatory burden was significantly reduced in the smooth muscle CaMKIIδ knockout animals as assessed histomorphometrically by the extent of inflammatory infiltrate, and by BALF quantification of the classic Th2 cytokine IL-13. Although the mechanisms by which CaMKIIδ deletion in smooth muscle decreases the net inflammatory response remain to be determined, it is possible that signaling via this kinase promotes transcription or release of pro-inflammatory cytokines and/or chemokines from ASM [30] . In vitro studies have emphasized cytokine-induced proinflammatory functions of ASM resulting in production of leukocyte adhesion molecules such as ICAM-1 or VCAM-1 and/or cytokines (e.g., IL-6 and IL-8) and chemokines (e.g., RANTES and eotaxin-1) [1, 9, 23, 36, 43, 49] , and limited pharmacological studies support a function for CaMKIImediated signaling in promoting these effects [30] . In this study, in vitro treatment of ASM cells with an inflammatory cytokine cocktail promoted transcription of the proinflammatory cytokine IL-33. This upregulation of IL-33 expression is dependent on smooth muscle CaMKIIδ as IL-33 expression was attenuated in CaMKIIδ knockout cells. This finding supports a role of ASM CaMKIIδ in promoting the inflammatory phenotype.
Inhibition of CaMKII activity has recently been shown to attenuate transcription of eotaxin in airway epithelia, with corresponding decreases in BALF content of eosinophils [44] . Our findings of increased peribronchial eosinophils in the smooth muscle CaMKIIδ knockouts may indicate compromised transmigration of these cells across the airway wall, a process driven by eotaxin and/or related factors produced by activated airway epithelia and ASM cells. Eosinophils have been found to further promote the Th2-mediated response perpetuating the inflammatory response [50] , potentially explaining the decreased BALF Th2 cytokine, IL-13 concentrations, inflammatory infiltrate, and ultimately AHR in allergen-challenged CaMKIIδ knockout animals.
Our respiratory mechanics studies at the later time point (7 days) support the hypothesis that ASM CaMKIIδ plays a complex role in the airways during allergen exposure. Clearly, CaMKIIδ upregulation in ASM has a pathological role in promoting or accelerating allergen-induced AHR. However, OVA-challenged CaMKIIδ knockout animals are hyperresponsive after exposure to methacholine at 7 days after final OVA challenge, while at this time point, we observed resolution of AHR in OVA-challenged wild-type animals. It is unclear whether at these later time points ASM CaMKIIδ plays a protective and necessary physiological role by helping in the resolution of airway injury, and further experiments are needed to resolve this issue. This idea is supported by the larger number of intact eosinophils in airway sections derived from OVA-challenged CaMKIIδ knockout as compared to OVAchallenged wild-type animals. Future studies identifying the molecular mechanisms involved in a potential dual role of ASM CaMKIIδ in promoting both inflammation and resolution of airway inflammation could further advance our understanding of the dynamic and complex process of airway inflammation.
We have previously defined selective increases in CaMKIIδ protein expression in arterial vascular smooth muscle (VSM) in response to balloon angioplasty injury [20] . One limitation of current approaches for studying ASM function using either the Tagln;Cre or Myh11;Cre transgenics is expression of Cre recombinase in lung vasculature [8, 26] . Given the close physical relationship between lung airways and blood vessels, and the fact that the vascular wall is a barrier to circulating leukocytes, we cannot rule out a contribution of CaMKIIδ in VSM as a contributing factor to any observed effects on OVA-induced leukocyte trafficking and inflammation. In VSM, CaMKIIδ promotes proliferation, migration, and ultimately vascular wall remodeling in response to injury [20, 21, 27 ]. An interesting possibility that remains to be tested is that CaMKIIδ upregulation in VSM promotes a proinflammatory function similar to that indicated by the present studies in ASM in the context of an atopic asthma model. Airway remodeling resulting from increased ASM growth and proliferation is a key feature of chronic asthma in humans and source of hyperreactivity [40, 59] . Whether or not allergen induced upregulation of ASM CaMKIIδ protein expression promotes airway remodeling will require additional studies using an alternative model that manifests with significant increases in ASM proliferation, hypertrophy, and wall thickness. 
